# A Study of SHR-1501 Combined With SHR-1316 in Patients With Advanced Tumors

> **NCT03995472** · PHASE1 · COMPLETED · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 14 (actual)

## Conditions studied

- Advanced Malignancies

## Interventions

- **DRUG:** SHR-1501
- **DRUG:** SHR-1316

## Key facts

- **NCT ID:** NCT03995472
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-02-14
- **Primary completion:** 2023-01-12
- **Final completion:** 2023-01-12
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2023-09-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03995472

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03995472, "A Study of SHR-1501 Combined With SHR-1316 in Patients With Advanced Tumors". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03995472. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*